Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1

INTRODUCTION: Integrase strand transfer inhibitor-based regimens (eg, containing dolutegravir [DTG]) are associated with weight/body mass index (BMI) increases among people living with HIV-1 (PLWH). Assessing antiretroviral therapy (ART)-related weight/BMI changes is challenging, as PLWH may experie...

Descripción completa

Detalles Bibliográficos
Autores principales: Donga, Prina, Emond, Bruno, Rossi, Carmine, Bookhart, Brahim K, Lee, Johnnie, Caron-Lapointe, Gabrielle, Wei, Fangzhou, Lafeuille, Marie-Hélène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377594/
https://www.ncbi.nlm.nih.gov/pubmed/37521004
http://dx.doi.org/10.2147/CEOR.S413800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377594/
https://www.ncbi.nlm.nih.gov/pubmed/37521004
http://dx.doi.org/10.2147/CEOR.S413800

Ejemplares similares